13 studies on AOD-9604 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 939 published AOD-9604 COA source records from third-party laboratories, covering 394 publicly attributable vendor identities. Across 823 records with positive numeric purity, the arithmetic mean is 99.08%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 12 positive purity results are below 90%; 66 records report measured amount more than 10% below the label. The latest recorded test date is 2026-09-23. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-09-25, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 2 mg | $5.50 | $5.50–$5.50 | $2.75 | 1 source · 1 offer |
| 5 mg | $15.17 | $13.00–$19.50 | $3.03 | 3 sources · 3 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-09-23. Aggregate calculated: 2026-09-25T03:28:47.908691+00:00. Calculation time is not a laboratory observation date.
Within that total, 217 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 24 | 99.66% | 0 of 22 (0.0%) 0 0% / not detected · 0 wrong compound · 2 unclassified | Reveal with Pro → | |
| #2 | 16 | 99.48% | 0 of 15 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → | |
| #3 | 13 | 98.74% | 0 of 13 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #110270 (99.97%) · #109969 (99.68%) · #109638 (99.01%) · #109847 (99.46%) · #108644 (99.25%) · #110540 (99.02%)
This finding is critically important for the integrity of anti-doping efforts worldwide. It confirms that the WADA hGH isoform immunoassay remains a reliable tool for detecting human growth hormone abuse, even with th…
The successful identification of AOD9604 in seized illicit preparations highlights the growing challenge posed by counterfeit and unregulated peptide drugs on the black market. This analytical capability is vital for …
This study provides compelling evidence that AOD9604, a specific fragment of human GH, can effectively reduce obesity and improve lipid metabolism without the adverse effects on glucose homeostasis typically associate…
This study provides crucial insights into the strategic elements that act as "gateways" for successful clinical development. The findings underscore the importance of novel target engagement and robust biomarker strat…
This comprehensive overview provided an invaluable, real-time snapshot of the global drug development landscape in 2004, offering critical insights for pharmaceutical companies, academic researchers, and policymakers …
This foundational review is critically important for researchers, pharmaceutical companies, and regulatory bodies seeking to effectively navigate the complex and high-stakes world of drug development. By systematicall…
This comprehensive review highlighted the diverse and innovative approaches being explored to combat obesity in the early 2000s. The identification of multiple drug classes, from central nervous system modulators to p…
This research provides a critical advancement for anti-doping efforts, offering a highly sensitive and reliable method for detecting AOD9604 abuse. The identification of a significantly more stable metabolite, CRSVEGS…
This novel analytical method represents a significant advancement for non-invasive biomarker discovery, particularly for diseases where small peptides serve as crucial indicators. By simplifying sample preparation and…
Free, no account — handy when you're working with AOD-9604.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$12 monthly or $33 lifetime
Create free account